

Report Cancer Cases

Participate in successful ongoing submission of cancer case information from CEHRT to a public health central registry for the entire EHR reporting period.

According to CMS, providers should contact their local or state public health agency for information and instructions on submitting public health related data to satisfy the Meaningful Use measures (See CMS FAQ #3605 <https://questions.cms.gov/faq.php?id=5005&faqId=3605>).

How to meet this measure using ONCOCHART -

Collecting and recording cancer information – Diagnose and stage all of your patients. Fill out and record your initial evaluations, end of treatment and follow-up narratives in their entirety. This includes the MDM sections.

Submitting cancer case information - This portion was not required to become a 2014 certified MU. For this reason, you will not be able to meet this measure using ONCOCHART.

[AREA]	[SITE - Genitourinary]	[ICD9 - Prostate]	[Stage Classification]	[T- Prostate]	[N- Prostate]	[M- Prostate]	[Prostate Histology]	[PSA Value]	[Gleason Score Sum]	[Tumor Margins]
Benign Conditions	Adrenal	185 Prostate All Cases	Clinical - No treatment of any type other than biopsy (vc)	NOT AVAILABLE	NOT AVAILABLE	NOT AVAILABLE	NOT AVAILABLE	NOT AVAILABLE	NOT AVAILABLE	NOT AVAILABLE
Bone	Bladder	233.4 Prostate Carcinoma In Situ	Clinical - Post Therapy - Surgical resection (vc)	TX Primary tumor cannot be assessed	IX Regional lymph nodes cannot be assessed	IX No distant metastasis	Adenocarcinoma	PSA < X	Gleason < X	Not specified
Breast	Kidney		Clinical - Post Therapy - Radiation therapy (vc)	T0 No evidence of primary tumor	IX No regional lymph node metastasis	M0 Distant metastasis	Adenocarcinoma, Acinar	PSA < 10	Gleason <= 6	Complete resection, clear margins
Central Nervous System	Kidney, Villin's Tumor		Clinical - Post Therapy - Chemotherapy (vc)	T1 Clinically inoperable tumor neither palpable nor visible by imaging	IX Regional lymph node metastasis	M1 Non-regional lymph node(s)	Adenocarcinoma, Acinar, Atrophic Variant	10 <= PSA < 20	Gleason 7	Complete resection, questionable margins
Chest	Pelvis		Clinical - Post Therapy - Combination - Any form of therapy (vc)	T1 Tumor incidental histologic finding in 5% or less of tissue resected	IX Regional lymph node metastasis	M1b Bone(s)	Adenocarcinoma, Acinar, Foamy Gland Variant	PSA >= 20	Gleason >= 8	Margins positive
Eye	Penis		Clinical - Recurrent (nc)	T1a Tumor incidental histologic finding in more than 5% of tissue resected		M1c Other site(s) with or without bone disease	Adenocarcinoma, Acinar, Mucinous			Limited resection
Gastrointestinal	Peritoneal Effusion		Clinical - Residual (nc)	T1b Tumor identified by needle biopsy			Adenocarcinoma, Acinar, Sacroamniotic Variant			Biopsy Only
Genitourinary	Prostate		Unknown	T1c Prostate cancer confined within the prostate. Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c.			Adenocarcinoma, Acinar, Signet Ring Variant			
Head And Neck	Renal Pelvis			T2 Prostate cancer confined within the prostate. Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c.			Adenocarcinoma, Acinar, Solid Pattern			
Lymphoid Tumors	Retropertoneum			T2 Prostate cancer confined within the prostate. Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c.			Adenocarcinoma, Ductal, Cribriform Pattern			
Metastatic Tumors	Seminal Vesicle			T2 Prostate cancer confined within the prostate. Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c.			Adenocarcinoma, Ductal, Papillary Pattern			
Skin	Testicle			T2 Prostate cancer confined within the prostate. Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c.			Adenocarcinoma, Ductal, Solid Pattern			
Soft Tissue Tumors	Ureter			T2 Prostate cancer confined within the prostate. Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c.			Adenocarcinoma, Mucinous			
Thyroid	Urethra			T2 Prostate cancer confined within the prostate. Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c.			Adenocarcinoma, Acinar, Lymphoepithelioma-Like Variant			
V Codes	Urothelial (Transitional Cell) Prostate			T2 Prostate cancer confined within the prostate. Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c.			Adenocarcinoma, Acinar, Oncocytic Variant			

Physical Examination

DRE PROSTATE : Nodular, hard prostate

E/M Exam | G/U-Male | DRE Prostate

Medical Decision Making: Data Review

PSA : 7

HISTOLOGY OF PROSTATE CANCER : Adenocarcinoma

SEXTANT BIOPSY : Adenocarcinoma, Grade 1, in 1 of 6 core biopsies

MDM Data Review | Tumor Markers | PSA

MDM Data Review | Pathology | Hist Prostate

MDM Data Review | Pathology | Sextant Biopsy